Retreatment with talimogene laherparepvec for advanced melanoma.

Journal Article (Journal Article)

Aim: Talimogene laherparepvec (T-VEC) is a genetically modified oncolytic herpesvirus approved for the treatment of unresectable, locoregionally advanced and recurrent melanoma. There is little relevant literature in the context of retreatment with T-VEC. Materials & methods: We reviewed four patients aged 71-87 years old with stage IIIB-IV melanoma at treatment who were rechallenged with T-VEC after experiencing recurrence of locoregional disease or prior treatment-limiting toxicity. Results: Cessation of initial treatment was due to one of the following reasons: severe adverse event (one case), mixed response (one case) or complete response (two cases). Three males and one female underwent T-VEC retreatment with a mean of 5.5 injection cycles. Three patients experienced a complete response to retreatment, while one experienced disease progression. Conclusion: Intralesional T-VEC may be effective and well-tolerated in patients who have completed prior T-VEC therapy.

Full Text

Duke Authors

Cited Authors

  • Hu, J; Masoud, SJ; Ravichandran, S; Beasley, GM; Mosca, PJ

Published Date

  • November 2020

Published In

Volume / Issue

  • 12 / 16

Start / End Page

  • 1167 - 1172

PubMed ID

  • 32840157

Electronic International Standard Serial Number (EISSN)

  • 1750-7448

Digital Object Identifier (DOI)

  • 10.2217/imt-2020-0029


  • eng

Conference Location

  • England